Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma

Yeul Hong Kim, Sang Won Shin, Byung Soo Kim, Jin H. Kim, Jong G. Kim, Young Jae Mok, Chong S. Kim, Ho S. Rhyu, Jin H. Hyun, Jun Suk Kim

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

BACKGROUND. Although the clinical efficacy of paclitaxel in the treatment of gastric carcinoma has not been clearly defined, recent reports have suggested a possible role in the treatment of upper gastrointestinal carcinomas in vitro and in vivo. In this study, the authors evaluated the efficacy and toxicity of a combination chemotherapy that included paclitaxel, 5-fluorouracil (5-FU), and cisplatin in the treatment of patients with advanced gastric carcinoma. METHODS. Forty-one gastric carcinoma patients with metastatic disease, unresectable advanced disease, or relapsed disease were treated with the following regimen, administered every 28 days: paclitaxel 175 mg/m2 by 3-hour intravenous (i.v.) infusion on Day 1, 5-FU 750 mg/m2 by 24-hour continuous i.v. infusion on Days 1-5, and cisplatin 20 mg/m2 by 2-hour i.v. infusion on Days 1-5. Twenty-six patients had measurable disease, and 15 had evaluable disease. All patients were assessable for toxicity. RESULTS. Twenty-one of the 41 patients (51%; 95% confidence interval [CI], 36.5-65.7%) demonstrated an objective response, including 4 complete responses (10%; 95% CI, 3.9-22.5%). Sixty-five percent of the patients with measurable disease (17of 26; 95% CI, 58-92.5%) and 27% of the patients with evaluable disease (4 of 15: 95% CI, 11.1-52.3%) achieved a complete response or a partial response. The median response duration was 17 weeks (range, 4-90 weeks), and the median survival duration for all patients was 26 weeks (range, 8 to 118+ weeks). The major toxicity of this treatment was myelosuppression with neutropenia of World Health Organization Grade 3 and 4 in 24% and 10% of the patients, respectively. Nonhematologic toxicity included mucositis, nausea/vomiting, diarrhea, neurotoxicity, and alopecia. Fluid retention occurred in two patients, and one patient had an anaphylatic reaction. Dose reduction was necessary for one patient, because Grade 4 neutropenia and mucositis occurred. CONCLUSIONS. Paclitaxel, 5-FU, and cisplatin was an active combination regimen in the treatment of advanced gastric carcinoma. The toxicity of this regimen was tolerable. Based on these findings, this combination regimen could be an attractive treatment in the preoperative setting.

Original languageEnglish
Pages (from-to)295-301
Number of pages7
JournalCancer
Volume85
Issue number2
DOIs
Publication statusPublished - 1999 Feb 2

Fingerprint

Paclitaxel
Combination Drug Therapy
Fluorouracil
Cisplatin
Stomach
Carcinoma
Therapeutics
Intravenous Infusions
Confidence Intervals
Mucositis
Neutropenia
Alopecia
Nausea
Vomiting
Diarrhea

Keywords

  • 5- fluorouracil
  • Advanced gastric carcinoma
  • Cisplatin
  • Combination chemotherapy
  • Paclitaxel

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. / Kim, Yeul Hong; Shin, Sang Won; Kim, Byung Soo; Kim, Jin H.; Kim, Jong G.; Mok, Young Jae; Kim, Chong S.; Rhyu, Ho S.; Hyun, Jin H.; Kim, Jun Suk.

In: Cancer, Vol. 85, No. 2, 02.02.1999, p. 295-301.

Research output: Contribution to journalArticle

Kim, Yeul Hong ; Shin, Sang Won ; Kim, Byung Soo ; Kim, Jin H. ; Kim, Jong G. ; Mok, Young Jae ; Kim, Chong S. ; Rhyu, Ho S. ; Hyun, Jin H. ; Kim, Jun Suk. / Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. In: Cancer. 1999 ; Vol. 85, No. 2. pp. 295-301.
@article{6b77f731d600431eabced292d0515616,
title = "Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma",
abstract = "BACKGROUND. Although the clinical efficacy of paclitaxel in the treatment of gastric carcinoma has not been clearly defined, recent reports have suggested a possible role in the treatment of upper gastrointestinal carcinomas in vitro and in vivo. In this study, the authors evaluated the efficacy and toxicity of a combination chemotherapy that included paclitaxel, 5-fluorouracil (5-FU), and cisplatin in the treatment of patients with advanced gastric carcinoma. METHODS. Forty-one gastric carcinoma patients with metastatic disease, unresectable advanced disease, or relapsed disease were treated with the following regimen, administered every 28 days: paclitaxel 175 mg/m2 by 3-hour intravenous (i.v.) infusion on Day 1, 5-FU 750 mg/m2 by 24-hour continuous i.v. infusion on Days 1-5, and cisplatin 20 mg/m2 by 2-hour i.v. infusion on Days 1-5. Twenty-six patients had measurable disease, and 15 had evaluable disease. All patients were assessable for toxicity. RESULTS. Twenty-one of the 41 patients (51{\%}; 95{\%} confidence interval [CI], 36.5-65.7{\%}) demonstrated an objective response, including 4 complete responses (10{\%}; 95{\%} CI, 3.9-22.5{\%}). Sixty-five percent of the patients with measurable disease (17of 26; 95{\%} CI, 58-92.5{\%}) and 27{\%} of the patients with evaluable disease (4 of 15: 95{\%} CI, 11.1-52.3{\%}) achieved a complete response or a partial response. The median response duration was 17 weeks (range, 4-90 weeks), and the median survival duration for all patients was 26 weeks (range, 8 to 118+ weeks). The major toxicity of this treatment was myelosuppression with neutropenia of World Health Organization Grade 3 and 4 in 24{\%} and 10{\%} of the patients, respectively. Nonhematologic toxicity included mucositis, nausea/vomiting, diarrhea, neurotoxicity, and alopecia. Fluid retention occurred in two patients, and one patient had an anaphylatic reaction. Dose reduction was necessary for one patient, because Grade 4 neutropenia and mucositis occurred. CONCLUSIONS. Paclitaxel, 5-FU, and cisplatin was an active combination regimen in the treatment of advanced gastric carcinoma. The toxicity of this regimen was tolerable. Based on these findings, this combination regimen could be an attractive treatment in the preoperative setting.",
keywords = "5- fluorouracil, Advanced gastric carcinoma, Cisplatin, Combination chemotherapy, Paclitaxel",
author = "Kim, {Yeul Hong} and Shin, {Sang Won} and Kim, {Byung Soo} and Kim, {Jin H.} and Kim, {Jong G.} and Mok, {Young Jae} and Kim, {Chong S.} and Rhyu, {Ho S.} and Hyun, {Jin H.} and Kim, {Jun Suk}",
year = "1999",
month = "2",
day = "2",
doi = "10.1002/(SICI)1097-0142(19990115)85:2<295::AID-CNCR5>3.0.CO;2-H",
language = "English",
volume = "85",
pages = "295--301",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma

AU - Kim, Yeul Hong

AU - Shin, Sang Won

AU - Kim, Byung Soo

AU - Kim, Jin H.

AU - Kim, Jong G.

AU - Mok, Young Jae

AU - Kim, Chong S.

AU - Rhyu, Ho S.

AU - Hyun, Jin H.

AU - Kim, Jun Suk

PY - 1999/2/2

Y1 - 1999/2/2

N2 - BACKGROUND. Although the clinical efficacy of paclitaxel in the treatment of gastric carcinoma has not been clearly defined, recent reports have suggested a possible role in the treatment of upper gastrointestinal carcinomas in vitro and in vivo. In this study, the authors evaluated the efficacy and toxicity of a combination chemotherapy that included paclitaxel, 5-fluorouracil (5-FU), and cisplatin in the treatment of patients with advanced gastric carcinoma. METHODS. Forty-one gastric carcinoma patients with metastatic disease, unresectable advanced disease, or relapsed disease were treated with the following regimen, administered every 28 days: paclitaxel 175 mg/m2 by 3-hour intravenous (i.v.) infusion on Day 1, 5-FU 750 mg/m2 by 24-hour continuous i.v. infusion on Days 1-5, and cisplatin 20 mg/m2 by 2-hour i.v. infusion on Days 1-5. Twenty-six patients had measurable disease, and 15 had evaluable disease. All patients were assessable for toxicity. RESULTS. Twenty-one of the 41 patients (51%; 95% confidence interval [CI], 36.5-65.7%) demonstrated an objective response, including 4 complete responses (10%; 95% CI, 3.9-22.5%). Sixty-five percent of the patients with measurable disease (17of 26; 95% CI, 58-92.5%) and 27% of the patients with evaluable disease (4 of 15: 95% CI, 11.1-52.3%) achieved a complete response or a partial response. The median response duration was 17 weeks (range, 4-90 weeks), and the median survival duration for all patients was 26 weeks (range, 8 to 118+ weeks). The major toxicity of this treatment was myelosuppression with neutropenia of World Health Organization Grade 3 and 4 in 24% and 10% of the patients, respectively. Nonhematologic toxicity included mucositis, nausea/vomiting, diarrhea, neurotoxicity, and alopecia. Fluid retention occurred in two patients, and one patient had an anaphylatic reaction. Dose reduction was necessary for one patient, because Grade 4 neutropenia and mucositis occurred. CONCLUSIONS. Paclitaxel, 5-FU, and cisplatin was an active combination regimen in the treatment of advanced gastric carcinoma. The toxicity of this regimen was tolerable. Based on these findings, this combination regimen could be an attractive treatment in the preoperative setting.

AB - BACKGROUND. Although the clinical efficacy of paclitaxel in the treatment of gastric carcinoma has not been clearly defined, recent reports have suggested a possible role in the treatment of upper gastrointestinal carcinomas in vitro and in vivo. In this study, the authors evaluated the efficacy and toxicity of a combination chemotherapy that included paclitaxel, 5-fluorouracil (5-FU), and cisplatin in the treatment of patients with advanced gastric carcinoma. METHODS. Forty-one gastric carcinoma patients with metastatic disease, unresectable advanced disease, or relapsed disease were treated with the following regimen, administered every 28 days: paclitaxel 175 mg/m2 by 3-hour intravenous (i.v.) infusion on Day 1, 5-FU 750 mg/m2 by 24-hour continuous i.v. infusion on Days 1-5, and cisplatin 20 mg/m2 by 2-hour i.v. infusion on Days 1-5. Twenty-six patients had measurable disease, and 15 had evaluable disease. All patients were assessable for toxicity. RESULTS. Twenty-one of the 41 patients (51%; 95% confidence interval [CI], 36.5-65.7%) demonstrated an objective response, including 4 complete responses (10%; 95% CI, 3.9-22.5%). Sixty-five percent of the patients with measurable disease (17of 26; 95% CI, 58-92.5%) and 27% of the patients with evaluable disease (4 of 15: 95% CI, 11.1-52.3%) achieved a complete response or a partial response. The median response duration was 17 weeks (range, 4-90 weeks), and the median survival duration for all patients was 26 weeks (range, 8 to 118+ weeks). The major toxicity of this treatment was myelosuppression with neutropenia of World Health Organization Grade 3 and 4 in 24% and 10% of the patients, respectively. Nonhematologic toxicity included mucositis, nausea/vomiting, diarrhea, neurotoxicity, and alopecia. Fluid retention occurred in two patients, and one patient had an anaphylatic reaction. Dose reduction was necessary for one patient, because Grade 4 neutropenia and mucositis occurred. CONCLUSIONS. Paclitaxel, 5-FU, and cisplatin was an active combination regimen in the treatment of advanced gastric carcinoma. The toxicity of this regimen was tolerable. Based on these findings, this combination regimen could be an attractive treatment in the preoperative setting.

KW - 5- fluorouracil

KW - Advanced gastric carcinoma

KW - Cisplatin

KW - Combination chemotherapy

KW - Paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=0032948714&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032948714&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(19990115)85:2<295::AID-CNCR5>3.0.CO;2-H

DO - 10.1002/(SICI)1097-0142(19990115)85:2<295::AID-CNCR5>3.0.CO;2-H

M3 - Article

C2 - 10023695

AN - SCOPUS:0032948714

VL - 85

SP - 295

EP - 301

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 2

ER -